Clarivate PLC Investor Event Transcript, Nov 18, 2026
Clarivate PLC (CLVT)
Clarivate expects free cash flow to grow 10% to 15% in 2027 from where it exits this year, helped by lower one-time transaction costs, lower cash interest and CapEx falling under 10% of revenue. A tender offer ended with a total $533 million debt repurchase, and the company expects about three and a half times leverage by the end of 2027. AI summary
Conference Transcript - CLVT 2026-11-18
Operator
Good morning, everyone.
Ashish Shabhadra, Analyst — RBC Capital Markets
Hi, I'm Ashish Sabhadra, and I cover information services company at RBC Capital Market. We are excited to host Clarivate's management team. Thank you for giving us this opportunity. Matty, if you want to kick it off with the...
Matitiahu Shem Tov, CEO
Ashish, thank you for asking us today. This is an important point in the Clarivate transformation. Over the last two years, I've been a CEO for two years, we've taken some very meaningful steps, strengthening and simplifying the company. We've rationalized the portfolio. We completed the vestige of life science and health. We have significantly increased the subscription base on the revenue to 93% from 79. We had some substantial progress strengthening our balance sheet. You'll hear more about this one. At the same time, we have sharpened our go-to-market and execution. Particularly around AI, we've introduced more than 80 different products or AI-enabled products that we believe will bring the company to a better and improved organic growth. So we enter to the next phase of the company, more focused, centered around the two leading IP and A&G sectors that we have. Clear path to sustainability, organic growth, and long-term shareholder value. And thank you again for hosting us today here.
Speaker 0
Shish and...
Matitiahu Shem Tov, CEO
Yeah, looking forward to the conversation.
Ashish Shabhadra, Analyst — RBC Capital Markets
Sounds great. Thanks for those prepared remarks, and that would be a good segue into my questions. You talked about your AI initiatives around AT agents. Can you talk about how do you think about that driving better value proposition for your customers, but also your ability to monetize some of those AI agents?
Matitiahu Shem Tov, CEO
No, definitely. We went into a journey introducing AI products. I mean, we've been in the AI for two or three years. We started with creating a small focus group of AI, and we created a center of excellence for AI introduction. And ever since, we have been product by product using the same methodology. We've done this in the mind of with AI introduction, with the 80 different products that are now AI enabled. We will drive better retention rate for our customers. That's key for us. Let's not forget we are running $2 billion businesses, 93% of recurring. So improving retention, it's very important for us. So through AI introduction and AI enabling our product line, we've managed to increase, and we are constantly increasing the retention rate. We are now at 94% retention for our customer base. It's also the AI introduction of the product. It allows us to increase the upsell opportunities, win new logos over time. So we are pretty upbeat, but we believe we can grow the organic revenue to a better market position.
Ashish Shabhadra, Analyst — RBC Capital Markets
That's very helpful, Kalar. And we'll talk about more of your AI initiatives as we go through the individual segment. But I wanted to just first start off at a higher level, talking about the organic growth. Organic growth improved 30 basis point to 1.8%. You've talked about pricing and volume as levers. Can you just help us understand how do we think about the pricing versus the volume dynamic? No, I think- So ACV,
Matitiahu Shem Tov, CEO
we see ACV as a great, this is the leading indicator for the growth of the company, the ACV. We've been on a journey improving ACV through better retention, through better product introduction, so more and more AI, winning new logo. Yes, and it's also supported by price increase.
Ashish Shabhadra, Analyst — RBC Capital Markets
Okay, that's helpful. And thanks for clarifying. I meant ACV, not revenue, so ACV growth improving. Just in terms of restructuring, as you said, you've done a number of restructuring. You've completed your life sciences and healthcare divestiture. Most of the A&G book wind down is behind you. What is remaining in terms of any inorganic disposals in 2027?
Matitiahu Shem Tov, CEO
Nothing significant is coming up. We are very pleased with the progress on the divestiture. We walk away from the one-time books, the one-time policy. It was choppy. It wasn't really predictable, and it was really a great cash flow. So walk away with this. We've run a process to sell the life science business. We're very pleased with the outcome. We closed the deal. We just paid down the debts, and we are making improvements on the ratio of the debts to EBITDA. So we're pleased. We do have some nominal small things that we want to further divest, but it's nothing significant.
Ashish Shabhadra, Analyst — RBC Capital Markets
Okay, that's very helpful. You previously talked about taking ANG to 3% to 4% revenue growth and IP to 4% to 5% revenue growth. Are those still reasonable targets?
Matitiahu Shem Tov, CEO
Definitely, definitely. This is a reasonable target. ANG is closer to target, so we're going to end up the year with 2% ACV growth for 2026. We'll definitely see us going to mid-signal digit on both segments over time. This is definitely the objective. That's great.
Ashish Shabhadra, Analyst — RBC Capital Markets
So maybe we can drill down further on the ANG or IP side first. If you can just talk about the health of the IP or patents-enforced market, how's that?
Matitiahu Shem Tov, CEO
So it's flat to growing low single digits. So IP, you know, patent-enforced is flat to growing low single digits. But I think I want to take a bigger perspective of the IP business. We are very unique in the IP area. We are the only vendor at the... that are actually setting The three types of services that we provide. The annuity business. Let's not forget that annuity business is not going to be disrupted by AI. This is a must-have, critical, non-deferrable, non-discretionary service to renew the patent. We actually renewing the patents of the top, you know, corporate around the world that actually giving us a patent book and say, go renew it in 200 different jurisdictions. That's a great business. It's tech enabled services. It's not really information services. So we are in the business of renewing patent. This is half of our IP business, renewing the business. On top of this, we have the software, the IPMS software that supports, it's like a small ERP system, or basically not as small, an ERP system for IP, and then we have the intelligent business, so we have annuities, so annuities, that's the patent renewals, the software, and the intelligent, and we are the only vendor, and they are the biggest. It's a good business. It went off track in the last years. With Simon coming back, with all his experience, Simon has been running CPA for five years. He managed to grow the business. With his passion and with knowledge and with the momentum from AI, we believe we can take the business back to a mid-single digit over time.
Ashish Shabhadra, Analyst — RBC Capital Markets
That's great. And we've already started to see that, right? IPACV turned positive for the first time in several years. And so can you help understand what really drove that, like how much of it was retention, pricing, new logos?
Speaker 0
Yeah, it was a combination of factors there. As Mahdi mentioned, with Simon coming back in, he knows that business well. He has deep relationships in there, and it was a critical priority for him to say, well, we want to grow. But first, we had to get it to positive, and then from positive, we can get it to growth. And so the real focus there was a couple of fronts. It was on, you know, retention, you know, then going out and attracting, you know, new business as well, and then just doing what we can from a price perspective. So as you said, we were pleased in the first quarter and I think, you know, three plus years that we'd seen ACV for the IP business return to growth. It was humble. We expect to see that continue to grow here in the future.
Ashish Shabhadra, Analyst — RBC Capital Markets
That's great. As you mentioned, or both of you have mentioned Simon coming on, there were also some organizational changes that he did. Can you just talk about any kind of organizational changes and how that positions that business going forward?
Matitiahu Shem Tov, CEO
Yeah, so Simon has been in the business for 20 years, five years as a leader of the business, just coming back. He ran his own. Value creation plan. He's done an assessment for the product. He's done an assessment for the team, and he decided to accelerate two things. One is the go-to-market. His decision, and I was highly supported, you've seen his organization, to cut the GTM into two, North America and international. Actually, it's working well so far because of the new… You know, extra attention that we go to GTM. But Simon has also done some other changes, and one of them is the acceleration and the extra attention to introduction of IP1. IP1 is, in fact, a game changer for the IP segment. Let's not forget, as I mentioned before, we have annuities, software, and intelligence. And IPARM started as a next-generation intelligence solution. We have the underlining data for trademarks, for patent, and for litigation data. We put everything behind one native-born AI capabilities, and here we got IPARM. This is how it started. We have 40 development partners for that. It's already in market. And I think you go beyond this ambitious behind IP. It's going beyond just intelligence. It's also providing some agentic capabilities to our customers. For example, if an IP expert needs to do an, you know, freedom to operate analysis, he can just go into IP1 and do this using the identity capabilities of IPR, IP1 on one hand, and the data assets on the other, right? So that's very excited about it. We'll hear more and more about this. And we'll look, yeah, on IPR, IP1 is going to be a game changer for IP.
Ashish Shabhadra, Analyst — RBC Capital Markets
That's great. And that was going to be my next follow-up question on IP1. Is the pilot launch in November? Has it launched already? And then the GA, is that first quarter, are you still on track?
Matitiahu Shem Tov, CEO
Yeah, definitely. There's something to say about IP1 that is available in two different flavors. One is we allow customers to use our own IP1 application with the underlying data. And with our own AI capabilities, but we also enable IP1 through the generic LLM, Microsoft Copilot, Entropic, and others, people will be able to use IP1 through those third-part generic LLM without compromising our data. This is key. We can do that. We keep the data. We don't give the data to the LLMs. It's just going to be done through MCPs.
Ashish Shabhadra, Analyst — RBC Capital Markets
Okay, okay.
Matitiahu Shem Tov, CEO
Now that's helpful.
Ashish Shabhadra, Analyst — RBC Capital Markets
You obviously talked about 40 plus development partners. Can you talk about the pipeline, the customer pipeline? How many people, how many companies are part of the initial pilot, but also the pipeline, customer pipeline for IP1?
Matitiahu Shem Tov, CEO
No, it's pretty, there's a lot of exciting about IP1. I think we mentioned in public that we have 151 customers located, but it's growing. There's a big momentum. I'm a big fan of Momentum. There's a lot of excitement. We're going for a long time. We are actually going on the offense with IP as opposed to what was done here before and opened the doors. And in fact, there are some customers that over the years have left us and now knocking back on our doors to hear more and to explore the opportunity to license IP1. That's a big change. That's great.
Ashish Shabhadra, Analyst — RBC Capital Markets
So as you mentioned, there's an opportunity for you to win new business, like winbacks, new logos. Is there also an opportunity for you to upsell or cross-sell into your existing customer base when they use IP1? Can they use a broader set of your products?
Matitiahu Shem Tov, CEO
Definitely. IP1 is three things. One is new ACV dollars. Secondly, it's helping us with the renewals. You know, the Delwent renewals are going to do better because we are implementing IP1 in the Delwent environment, including the agentic capabilities. And then, certainly, it's increased our competitiveness of our product with the agentic capabilities of IP1.
Ashish Shabhadra, Analyst — RBC Capital Markets
That's great. And then maybe just on pricing, can you talk about your pricing strategy within IP? How do you think about pricing opportunity there?
Speaker 0
Yeah, no, the price is an important component of our ability to grow the ACV or the annual contract value. So that pricing component, we look at it on an annual basis. Now Simon leading the team meets with the product teams and the go-to-market teams. Everybody looks at it from what are the dynamics and what environment they're seeing out there in the marketplace, and then they'll set a target for the coming year. We've talked about that we've tried to achieve around a 3% price on an annual basis. We're tracking towards that for this year, and we'll look to do something similar or better for the coming year.
Ashish Shabhadra, Analyst — RBC Capital Markets
Okay. Okay. Now, that's great. Just switching gears, talking about ANG. ANG, again, Matty, as you pointed out, it's going to deliver 2% growth by the end of this year. It had 2% subscription growth in 3Q26. Can you just talk about the organic growth trajectory from here on, without necessarily giving guidance, but just how do we think about the tailwinds for the business going forward?
Matitiahu Shem Tov, CEO
No, it's a very... First of all, just to reiterate that A&G is a very strong, we have some very strong offering on A&G, the Web of Science, Web of Science Research Intelligence. Web of Science Research Intelligence is our new offering, you know, for intelligence on top of Web of Science. In helping us, again, with new ACVs retention and the corporate of Web of Science, we're pretty upbeat about the opportunity of Web of Science going forward. Strong offering there, strong offering on the content side as well, with, again, with new AI capabilities, new product expansion and extension, and then the ERP from the libraries. We feel good about that traditionally, and we believe we can go to mid-signities over time.
Ashish Shabhadra, Analyst — RBC Capital Markets
That's great. Can you just talk about the state of the budget for your A&G customers? How are the budgets shaping up for next year? It's stable.
Matitiahu Shem Tov, CEO
Yes, there are some concerns from different... For different, in different jurisdictions, but let's not forget, those are mission-critical solutions. We were smart to move away from the one-time, because these one-time books, one-time paths that we've done in the past are all gone. So we are left with mission-critical subscription-based product, which is helping us on the retention and on the growth of ANG. So we feel good about it, yeah.
Ashish Shabhadra, Analyst — RBC Capital Markets
Okay. And then, Matty, you obviously mentioned from a product perspective, the web of science intelligence product, research intelligence product that gaining a lot of traction. You've talked about securing 100 plus institutional wins and a $20 million pipeline. The question is, what's really driving that momentum? You obviously talked about, is it the product, the product that's resonating with your customer? What's driving that kind of strong momentum? Are these like competitive wins or are these customers that historically haven't used your product?
Matitiahu Shem Tov, CEO
So basically, we took a decision. We have some small legacy products within the research environment. We took an approach about a year plus ago saying, let's cannibalize our own customer base, our own base, using all those small, small, you know, point solution and introduce more comprehensive new AI bond product with necessary uplift because we want to increase the ACV. We set up and develop a partnership with a lot of different customers, end up with Web of Science Research Intelligence. There's a lot of excitement and a lot of momentum. And the beauty of it is that we sell our customers in 25 different countries. So it's kind of amazing to see that something that we just introduced about six months ago, over 100 customers and counting in 25 locations, It means that we are doing something right with Web of Science Research Intelligence and helping us to retain Web of Science as well and for Web of Science to be more competitive.
Ashish Shabhadra, Analyst — RBC Capital Markets
That's great color. You obviously talked about embedding AI capabilities within that product. Can you just give some color around what kind of AI capabilities does it offer and how that's driving better customer value proposition?
Matitiahu Shem Tov, CEO
Agente capabilities, we do the job, we're helping the customer to do the job. First of all, the intuition, everything today is, you know, is conversational, conversational AI. This is one side of it. And then we let the machine do the work for us with the agente capabilities, different use cases for different products. If it's IP1, even Web Science Research Intelligence, we're also now implementing this in other products as well, agente capabilities to help people do the job.
Ashish Shabhadra, Analyst — RBC Capital Markets
Yeah. Okay, no, that's helpful. And then just on a similar topic of AI and agentic AI, can you talk about how you're enabling Clarivate data being available through, let's say, Microsoft Copilot, through the IP1 connector? Can you just talk about how you're enabling better consumption of your data through different LLMs as well as Microsoft Copilot? Okay?
Matitiahu Shem Tov, CEO
So first of all, we do not... Give the data to the LLM. Our data which is proprietary to us is fundamental to us. We do not compromise. Customer can decide. If they want to consume our data through our own application, for example, IP1 or Web of Science, or they want to do this through third-party, like through the generic LLMs, like OpenAI, Microsoft Copilot, or Entropic, that's for the customer to decide. At some, we'll decide our belief that the bigger customer may want to consume this through their own corporate, through their own enterprise license of AI, and the smaller customers, the medium-sized, the smaller customers, will be going to consume our data through our own AI capabilities. So traction is from... Both sides, yeah. And we do this, obviously, through MCPs, yeah.
Ashish Shabhadra, Analyst — RBC Capital Markets
Yeah, no, that was going to be my follow-up question. Is this through MCP? And if it is, then how do you charge for that MCP compared to like if the customer was getting this data through API versus MCP? Do you charge more for it? Or how have you seen consumption go up with the customer consuming it through MCP?
Matitiahu Shem Tov, CEO
I think it's evolving. It's still evolving. It's the new thing that we are actually experimenting with customers and the feedback and helping some help that we do take from third party. Definitely, it's an evolving. Definitely, it's a new revenue stream for us.
Ashish Shabhadra, Analyst — RBC Capital Markets
Okay. No, that's very helpful. We've talked a lot about implementing AI solution and customer facing, but can you also talk about leveraging AI internally to drive efficiency?
Speaker 0
Yeah, no, it's really a question, Ashish. When this whole authentic AI journey started a couple of years ago, we were first and foremost focused on it from a product perspective, and that's what you kind of heard from us early on. But we started to work on that from an internal perspective as well. And I think that's some of the efficiencies we've gained from that over the past couple of years have helped with the margin expansion that you're seeing this year. But we believe there's continued opportunity, especially in the areas of software development, content aggregation or content cleansing. There's opportunities from finance and other opportunities across the shared service functions to be more efficient. And as we do that, as we gain capabilities there, in some cases, it allows us to redeploy to higher value-added, you know, function or support. And it's all in the name of how do we better support the commercial teams to drive that organic revenue growth.
Ashish Shabhadra, Analyst — RBC Capital Markets
Okay. Now, that's very helpful. And when you think about the margins, right, margins in the third quarter were close to 45%, which is very much closer to your adjusted targets. How do you think about margin expansion opportunities going forward?
Speaker 0
Yeah, no, we've been working hard to get to this, I'll call this approximate 45% level. And that's, you know, been an important place and part of the journey for us to get to. And now as we've done the work over these past couple of years, as we've also, you know, turned some of our, you know, revenue. You know, products and offerings to a growth profile. The key for us now is really to say, how do we grow from, you know, low digits, you know, barely flat now to where we want to be in the future, as you talked about with Monty when we started. And so we want to maintain that margin. But these next couple of years, we really want to focus on accelerating and, you know, growing organically. And so we'll continue to maintain the margin where it's at. We think there's plenty of opportunity to maintain margin and adequately invest and give our sales teams, our product teams, the commercial teams opportunities to see accelerated organic revenue growth.
Ashish Shabhadra, Analyst — RBC Capital Markets
That's great. And then question on free cash flow. Can you comment on the free cash flow conversion? How should we think about the guidance for this year, but also going forward as some of the restructuring costs come off? How do we think about the free cash flow conversion going forward?
Speaker 0
Yeah, ultimately, free cash flow is critical for us. It's been an area where we've been looking to improve that over the past couple of years. I think we've made good progress on that. For this coming year, there's an early perspective or early insight into 2027 that we provided just a month ago in our earnings is that we expect for 2027 to be able to grow free cash flow from where we exit this year by about 10% to 15% in this coming year. And I think we are going to have the opportunity to do that in three primary areas. To get the business sold that we did this past year, the divestiture of LSNH, and some of the other wind-down activity, there was a higher amount of one-timer transactional costs that were a drag on free cash flow. That's going to go down significantly in this coming year. So that's the first area. Secondly, from an interest, cash interest or interest expense perspective, we made some debt reduction throughout the course of the year, but then we had the large tender offer and repayment and repurchase that we just completed here in November. We'll get the full-year benefit of that in 2027. So that's the second area where we'll see, you know, make a continued improvement in progress from 2026 to 2027. And then lastly, just from a CapEx perspective as well. We talked about that historically. Ellison H. was a little higher user of CapEx in investment than our other businesses. We've been up over 10% of CapEx. It's a percentage of revenue in the past. We'll see that get under 10% in 2027. That'll be the third area. And the three of those combined will get us to a 10% to 15% growth on free cash flow in 2027.
Ashish Shabhadra, Analyst — RBC Capital Markets
That's great color. And I think what is underappreciated is this 10 to 15% of free cash flow growth, despite divesting off your life sciences and healthcare business. So despite divesting off, you're driving higher free cash flow conversion. So now that's very helpful. And then how do you think about using the proceeds? As you said, you have a tender offer out. So maybe if you can provide more color on that, but also how do you plan to use your strong free cash flow? We'll see you next time.
Speaker 0
Yeah, you know, we've signaled that, you know, in 26, the priority was around using our free cash flow to pay down debt. And we've already signaled that's going to be the priority for 2027 as well. And so with that, you know, nothing is coming due in 2027. But the next two near term maturities are our 2028 notes and our 2029 notes. And so it's really a matter of looking at those from, you know, what is the economic, you know, perspective for both of them. Also, then just which are the maturities that are coming due the quickest. And what's our estimates of free cash flow generation over the next couple of years. So you saw in the tender offer we just did, we went out at about an 80-20 split between the 28s and the 29s, had good participation in that tender offer, ended up upsizing it by another $33 million to go out with a total $533 million debt repurchase. But there's more that we'll continue to do. We gave an indication that for 2027, we expect to end the year about three and a half times leverage. And to do that, we need to focus on free cash flows, on debt repayment as we move through 2027. And we'll have a focus on just the near-term maturities, which will become the 28th as we get into 2027. And so that will be an area we'll focus on through the coming year.
Ashish Shabhadra, Analyst — RBC Capital Markets
Okay, that's helpful. Cool. Just switching back and going to the AI initiatives, we talked about a lot of those different AI initiatives, but I was just wondering, like, outside of IP1 and web of research intelligence, how do you think about the other AI initiatives or the roadmap for AI initiatives over the midterm? Yes. So we have…
Matitiahu Shem Tov, CEO
So, The headlines are IP1 and Web of Science Research Intelligence, but we have additional AI initiatives going on the product side all across. We have won a big contract from the USPTO Trade Vision, like Trendmark Vision. This is AI capabilities of a new product. We want to work for RiskMark, another product that we have on the IP side, and we constantly improve the others on the ANG side. We have WorldScience Research Intelligence, a prime one on research. We have a few AI new product initiatives. We've got one we call Progress Intelligence on the content side. We have a new product coming up called Sky River on the software side. So there are some additional in each area or sub-area of ours, sub-segment, there are additional AI initiatives ongoing. Let's not forget, many of us come from a product engineering background as opposed to we have a lot of passion to product innovation. That's our roots for many of us. That's great. We'll keep it there. Thank you very much. Thanks, everyone. Thank you for your attention.
Operator
Thank you, Ashish. Thank you, Matty.